Recital 3, Commission Regulation (EU) No 122/2013 of 12 February 2013 amending Regulation (EC) No 1…

In forcesince 12 Feb 2013

A substance should only be included in the list as a ‘substance bringing added clinical benefit’ where it provides a clinically relevant advantage based on improved efficacy or safety or a major contribution to treatment. This may be the result, inter alia, of different modes of actions, different pharmacokinetic or pharmacodynamic profiles, different lengths of treatment or different routes of administration.